Basit öğe kaydını göster

Pregnancy incidence and therapy exposure in relapsing forms of MS: a 12-year retrospective multicentre analysis

dc.contributor.authorJokubaitis, V. G.
dc.contributor.authorHavrdova, E.
dc.contributor.authorHorakova, D.
dc.contributor.authorIzquierdo, G.
dc.contributor.authorKalincik, T.
dc.contributor.authorvan der Walt, A.
dc.contributor.authorPucci, E.
dc.date.accessioned2020-06-21T13:18:14Z
dc.date.available2020-06-21T13:18:14Z
dc.date.issued2017
dc.identifier.issn1352-4585
dc.identifier.issn1477-0970
dc.identifier.urihttps://hdl.handle.net/20.500.12712/12227
dc.description7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS) -- OCT 25-28, 2017 -- Paris, FRANCEen_US
dc.descriptionOreja-Guevara, Celia/0000-0002-9221-5716; Lugaresi, Alessandra/0000-0003-2902-5589; Turkoglu, Recai/0000-0001-9724-851X; McCombe, Pamela/0000-0003-2704-8517;en_US
dc.descriptionWOS: 000413730200200en_US
dc.description.abstract…en_US
dc.description.sponsorshipEuropean Comm Treatment & Res Multiple Sclerosis, Americas Comm Treatment & Res Multiple Sclerosisen_US
dc.description.sponsorshipMS Research Australia Fellowship; BiogenBiogen; Merck SeronoMerck SeronoMerck & Company; NovartisNovartis; GenzymeGenzyme Corporation; Teva; Charles University in Prague [PRVOUK-P26/LF1/4]; Czech Ministry of HealthMinistry of Health, Czech Republic [NT13237-4/2012]; NHMRCNational Health and Medical Research Council of Australia; EMD SeronoMerck Serono; Bayer ScheringBayer AG; Sanofi/Genzyme; Associazione Italiana Sclerosi MultiplaFondazione Italiana Sclerosi Multipla (FISM); Teva Neurosciences; Mitsubishi; ONO Pharmaceuticals; Almirall; Sanofi AventisSanofi-Aventis; UCBUCB Pharma SA; LundbeckLundbeck Corporation; Associazone Marchigana Sclerosi Multipla e altre malattie neurologiche; Novartis Pharma; MSBase Foundationen_US
dc.description.sponsorshipVGJ is supported by an MS Research Australia Fellowship, and has received conference travel support from Teva, Novartis, Biogen, Biogen, Merck, and speakers honoraria from Biogen, Novartis and Merck.; EH Received speaker honoraria and consultant fees from Biogen, Merck Serono, Novartis, Genzyme and Teva, as well as support for research activities from Biogen, Merck Serono and research grants from Charles University in Prague (PRVOUK-P26/LF1/4 and Czech Ministry of Health (NT13237-4/2012).; AVDW receives funding from the NHMRC. She has received travel support, speakers honoraria and served on advisory boards for Biogen, Merck, Novartis, Genzyme and Teva.; ALN grant support from Novartis, Biogen and Merck Serono and has received consulting fees from EMD Serono.; MT Received travel grants from Merck Serono, Novartis, Bayer Schering and Teva and has participated in clinical trials by Sanofi-Aventis, Roche and Novartis.; PS Received travel grants and speaking honoraria from Bayer Schering, Biogen, Merck Serono, Novartis, Sanofi/Genzyme and Teva.; AL Bayer, Biogen, Genzyme, Merck Advisory Board Member. She received travel grants and honoraria from Bayer, Biogen, Merck, Novartis, Sanofi and Teva, research grants from the Associazione Italiana Sclerosi Multipla.; FGM Received honoraria or research funding from Biogen, Genzyme, Novartis, Teva Neurosciences, Mitsubishi and ONO Pharmaceuticals.; CR Received research funding, compensation for travel or speaker honoraria from Biogen, Novartis, Genzyme and Almirall.; EP Served on scientific advisory boards for Genzyme and Biogen; he has received honoraria and travel grants from Sanofi Aventis, UCB, Lundbeck, Novartis, Bayer Schering, Biogen, Merck Serono, Genzyme and Teva; he has received travel grants from Associazone Marchigana Sclerosi Multipla e altre malattie neurologiche.; VVP Served on advisory boards for Biogen, Novartis Pharma and Sanofi-Genzyme; has received travel grants and consultancy fees from Biogen, Bayer Schering, Sanofi Aventis, Merck Serono, Sanofi-Genzyme and Novartis Pharma; has received research grants from Bayer Schering.; This study was supported by the MSBase Foundation and Biogen.en_US
dc.language.isoengen_US
dc.publisherSage Publications Ltden_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titlePregnancy incidence and therapy exposure in relapsing forms of MS: a 12-year retrospective multicentre analysisen_US
dc.typeconferenceObjecten_US
dc.contributor.departmentOMÜen_US
dc.identifier.volume23en_US
dc.identifier.startpage130en_US
dc.identifier.endpage132en_US
dc.relation.journalMultiple Sclerosis Journalen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster